Personal information

Emails & domains

Verified email domains

Other IDs

SciProfiles: 4020474

Activities

Collapse all

Employment (1)

Walter Reed Army Institute of Research: Silver Spring, MD, US

1989-09-29 to present | Senior Scientist, Biochemistry Section (Diarrheal Disease Research)
Employment
Source: Self-asserted source
K. Ross Turbyfill

Education and qualifications (2)

University of Maryland: College Park, MD, US

1990-09 to 1996-05 | Master of Science (Microbiology)
Education
Source: Self-asserted source
K. Ross Turbyfill

Georgia State University: Atlanta, GA, US

1984-09 to 1988-05 | Bachelor of Science (Biology)
Education
Source: Self-asserted source
K. Ross Turbyfill

Professional activities (4)

American Chemical Society: Washington, DC, US

Regular Member
Membership
Source: Self-asserted source
K. Ross Turbyfill

American Association of Pharmaceutical Scientists: Arlington, Virginia, US

2022-01-12 to present
Membership
Source: Self-asserted source
K. Ross Turbyfill

Parenteral Drug Association: Bethesda, Maryland, US

2018-04-26 to present | Plus Standard
Membership
Source: Self-asserted source
K. Ross Turbyfill

American Society for Microbiology: Washington, DC, US

1990-02-06 to present | Contributing
Membership
Source: Self-asserted source
K. Ross Turbyfill

Works (20)

Safety, Tolerability, and Immunogenicity of the InvaplexAR-Detox Shigella Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: Study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical Trial

Vaccines
2025-01-08 | Journal article
DOI: 10.3390/vaccines13010048
Contributors: Geert V. T. Roozen; Nsofwa Sukwa; Masuzyo Chirwa; Jessica A. White; Marcus Estrada; Nicole Maier; Kevin R. Turbyfill; Renee M. Laird; Akamol E. Suvarnapunya; Aicha Sayeh et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

GMP manufacture of Shigella flexneri 2a Artificial Invaplex (InvaplexAR) and evaluation in a Phase 1 Open-label, dose escalating study administered intranasally to healthy, adult volunteers

Vaccine
2023-10 | Journal article
DOI: 10.1016/j.vaccine.2023.08.051
Part of ISSN: 0264-410X
Contributors: Christopher Duplessis; Kristen Clarkson; K. Ross Turbyfill; Ashley Alcala; Ramiro Gutierrez; MarkSRiddle; Tida Lee; Kristopher Paolino; Hailey P. Weerts; Amanda Lynen et al.
Source: Self-asserted source
K. Ross Turbyfill

Development of the Shigella flexneri 2a, 3a, 6, and S. sonnei artificial Invaplex (Invaplex AR ) vaccines

mSphere
2023-08-24 | Journal article
DOI: 10.1128/msphere.00073-23
Contributors: K. Ross Turbyfill; Kristen A. Clarkson; Edwin V. Oaks; Daniel V. Zurawski; Anthony R. Vortherms; Robert W. Kaminski; Alfredo G. Torres
Source: check_circle
Crossref

From Concept to Clinical Product: A Brief History of the Novel <i>Shigella</i> Invaplex Vaccine&rsquo;s Refinement and Evolution

Vaccines
2022-04 | Journal article | Author
DOI: 10.3390/vaccines10040548
Contributors: K. Ross Turbyfill; Kristen A. Clarkson; Edwin V. Oaks; Robert Kaminski
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 2)‎

Artificial invaplex formulated with deacylated lipopolysaccharide

USPTO
2021-01-05 | Patent
PAT:

10,881,684
Source: Self-asserted source
K. Ross Turbyfill

Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of Shigella Artificial Invaplex.

mSphere
2018-03-28 | Journal article
DOI: 10.1128/msphere.00583-17
PMID: 29600284
PMC: PMC5874444
Source: Self-asserted source
K. Ross Turbyfill

Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.

Clinical and vaccine immunology : CVI
2014-01-08 | Journal article
DOI: 10.1128/cvi.00683-13
PMID: 24403527
PMC: PMC3957668
Source: Self-asserted source
K. Ross Turbyfill

Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine.

Vaccine
2011-07-23 | Journal article
DOI: 10.1016/j.vaccine.2011.07.033
PMID: 21787825
Source: Self-asserted source
K. Ross Turbyfill

Artificial invaplex

USPTO
2010-09-24 | Patent
PAT:

7,780,966
Source: Self-asserted source
K. Ross Turbyfill

Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccines.

Clinical and vaccine immunology : CVI
2009-02-18 | Journal article
DOI: 10.1128/cvi.00435-08
PMID: 19225079
PMC: PMC2668287
Source: Self-asserted source
K. Ross Turbyfill

Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a.

Vaccine
2008-01-17 | Journal article
DOI: 10.1016/j.vaccine.2007.12.040
PMID: 18276045
Source: Self-asserted source
K. Ross Turbyfill

Heterologous protection induced by immunization with invaplex vaccine

USPTO
2007-08-21 | Patent
PAT:

7,258,863
Source: Self-asserted source
K. Ross Turbyfill

Mucosal adjuvant properties of the Shigella invasin complex.

Infection and immunity
2006-05-01 | Journal article
DOI: 10.1128/iai.74.5.2856-2866.2006
PMID: 16622224
PMC: PMC1459713
Source: Self-asserted source
K. Ross Turbyfill

Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.

Vaccine
2005-12-05 | Journal article
DOI: 10.1016/j.vaccine.2005.11.040
PMID: 16364513
Source: Self-asserted source
K. Ross Turbyfill

Invaplex from gram negative bacteria, method of purification and methods of use

USPTO
2004-01-20 | Patent
PAT:

6,680,374
Source: Self-asserted source
K. Ross Turbyfill

Use of purified invaplex from gram negative bacteria as a vaccine

USPTO
2001-08-21 | Patent
PAT:

6,277,379
Source: Self-asserted source
K. Ross Turbyfill

Invaplex from gram negative bacteria, method of purification and methods of use

USPTO
2001-06-12 | Patent
PAT:

6,245,892
Source: Self-asserted source
K. Ross Turbyfill

Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine.

Infection and immunity
2000-12-01 | Journal article
DOI: 10.1128/iai.68.12.6624-6632.2000
PMID: 11083774
PMC: PMC97759
Source: Self-asserted source
K. Ross Turbyfill

Identification of epitope and surface-exposed domains of Shigella flexneri invasion plasmid antigen D (IpaD).

Infection and immunity
1998-05-01 | Journal article
DOI: 10.1128/iai.66.5.1999-2006.1998
PMID: 9573082
PMC: PMC108156
Source: Self-asserted source
K. Ross Turbyfill

Recognition of three epitopic regions on invasion plasmid antigen C by immune sera of rhesus monkeys infected with Shigella flexneri 2a.

Infection and immunity
1995-10-01 | Journal article
DOI: 10.1128/iai.63.10.3927-3935.1995
PMID: 7558301
PMC: PMC173552
Source: Self-asserted source
K. Ross Turbyfill

Peer review (3 reviews for 2 publications/grants)

Review activity for Microbial pathogenesis. (2)
Review activity for npj vaccines. (1)
How many people are using ORCID?